Roche and Schering-Plough have entered into a cross-licensing agreementthat they say settles all ongoing patent disputes between the firms regarding their respective peginterferon alfa products, Pegasys (peginterferon alfa 2a) and PegIntron (peginterferon alfa-2b).
As a result of the settlement, each party will license to the other intellectual property relating to the use of peginterferon alfa with the antiviral drug ribavirin. The development allows Roche and S-P to market their products without hindrance, as well as to have them manufactured by third parties. Financial terms were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze